Injectable Biomaterials for Treatment of Glioblastoma

Abstract

standard of care. Because GBM is a brain tumor, tumor resection is conducted using "maximally safe" surgical margins with the goal of removing all cancerous cells while leaving as much of the healthy parenchyma intact as possible. [5] This strategy is particularly important for GBM because damaging or removing the highly specialized healthy brain tissue will result in language, motor, or

Recent Biomaterial-Assisted Approaches for Immunotherapeutic Inhibition of Cancer Recurrence

“…7 Biomaterials have established themselves in regenerative medicine and tissue engineering, and their use after resection for preventing cancer recurrence is increasing. 143 They offer precise control over the kinetics and location of immunotherapeutic payloads. Numerous studies focus on local treatment to limit probable systemic toxicity and adverse effects.…”

“…Despite various advantages of cancer immunotherapy, there are some restrictions for this way of treatment: inadequate effective response by single immunotherapy, variations in response between different patients, and poor effect on cases with a large number of tumors due to the enormous tumor burden and tumor cells with low immune sensitivity . Biomaterials have established themselves in regenerative medicine and tissue engineering, and their use after resection for preventing cancer recurrence is increasing . They offer precise control over the kinetics and location of immunotherapeutic payloads.…”

Rationally designed drug delivery systems for the local treatment of resected glioblastoma

“…These biomaterials can form hydrogels by self-assembly or following chemical modification, and can be locally injected as gels or liquids that undergo sol-gel transition depending on the linking chemistries, the physical binding or upon exposure to environmental stimuli (e.g. pH, light, temperature or ionic strength) [89]. The drawbacks of these materials reside on processability problems, reduced opportunities to tune drug release kinetics and degradation by modifications of polymer composition [44].…”

Advances in Hydrogels of Drug Delivery Systems for Local Treatment of Brain Tumors

“…The Malignant brain tumors, including prevalent types such as glioblastoma, are histologically diverse and aggressively invasive neoplasms, leading to high morbidity rates [1]. Glioblastoma is categorized as a grade IV glioma according to World Health Organization (WHO) guidelines, with over two-thirds of primary brain tumors being aggressive in nature [2,3].…”